Intravitreal Dexamethasone Implant for Postvitrectomy Macular Edema: A Retrospective Cohort of Patients with Postvitrectomy Macular Edema Treatment
| Autor: | Gamze Ture, Ekrem Talay, Seda Karaca Adıyeke |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Angiogenesis Inhibitors Dexamethasone Macular Edema Cohort Studies Postoperative Complications Ophthalmology medicine Dexamethasone Intravitreal Implant Humans Pharmacology (medical) In patient Macular edema Aged Retrospective Studies Pharmacology business.industry Retrospective cohort study Vitreoretinal surgery Middle Aged medicine.disease Intravitreal Injections Female Implant business Tomography Optical Coherence medicine.drug |
| Zdroj: | Journal of Ocular Pharmacology and Therapeutics. 34:335-339 |
| ISSN: | 1557-7732 1080-7683 |
| DOI: | 10.1089/jop.2017.0107 |
| Popis: | To evaluate the clinical findings and the efficacy of dexamethasone intravitreal implant in patients with postvitrectomy macular edema.The records of 14 patients diagnosed with postvitrectomy macular edema unresponsive to first-line treatment, treated with intravitreal dexamethazone implant injection and followed at least 6 months between October 2011 and May 2016 were retrospectively reviewed. All patients underwent standard ophtalmological examination, fluorescein angiography, and optical coherence tomography. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressures (IOPs) were recorded at baseline, at first and sixth months after the injection.The mean BCVA, which was 0.2 ± 0.14 logMAR at baseline significantly increased to 0.44 ± 0.2 logMAR at first month (P = 0.05) and to 0.4 ± 0.22 logMAR at sixth month of intravitreal dexamethazone implant injection (P = 0.01). CMT was also significantly decreased to 368.3 ± 90.4 μm at first month and to 323 ± 84.6 μm at sixth month from pre-injection value of 520.7 ± 90.3 μm (P = 0.001 and P = 0.002, respectively). IOP significantly increased from was 15 ± 2.1 mmHg at baseline to 20.6 ± 5.4 mmHg at first month of intravitreal dexamethazone implant injection (P = 0.01).Dexamethazone implant treatment may reduce CMT and improve BCVA in cases with postvitrectomy macular edema. IOP should be regularly screened in these cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|